Beijing Balance Medical Technology Co

Beijing Balance Medical Technology Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Beijing Balance Medical Technology Co (688198.SS) as of Nov 2, 2026 is 31.82 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -18.47 % — a change of -272.31% (higher).

FCF Conversion

31.82 %

YoY

-272.31%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Beijing Balance Medical Technology Co is 2025 31.82 % . FCF Conversion Rate (FCF/EBITDA) of Beijing Balance Medical Technology Co was 2024 -18.47 % . It decreases by -272.31% higher compared to the previous year.

The Beijing Balance Medical Technology Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
154.90 CNY
Jan 1, 2019
98.06 CNY
Jan 1, 2020
76.20 CNY
Jan 1, 2021
8.34 CNY
Jan 1, 2022
25.24 CNY
Jan 1, 2023
10.88 CNY
Jan 1, 2024
-18.47 CNY
Jan 1, 2025
31.82 CNY
The Beijing Balance Medical Technology Co FCF Conversion history
YEARFCF ConversionYoY
31.82 %-272.31%
-18.47 %-269.75%
10.88 %-56.90%
25.24 %+202.54%
8.34 %-89.05%
76.20 %-22.30%
98.06 %-36.69%
154.90 %+96.38%
78.87 %-22.01%
101.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beijing Balance Medical Technology Co Stock analysis

What does Beijing Balance Medical Technology Co do? Beijing Balance Medical Technology Co., Ltd. generates revenue through the manufacture and sale of biotechnology products across three key therapeutic areas. The company's heart valve replacement and repair segment offers artificial biological heart valves and valve forming rings, while its congenital heart disease interventional therapy line includes cardiothoracic surgical biological patches, outflow tract single valve patches, and atrial defect occluders. The surgical soft tissue repair division provides neurosurgical biological patches and biological hernia patches. All products are sold primarily within China's domestic market to hospitals and medical institutions seeking advanced cardiovascular and surgical solutions. The firm's product portfolio targets medical professionals specializing in cardiac surgery, congenital heart defect correction, and soft tissue repair procedures. Hospitals and healthcare providers in China purchase these biotechnology solutions for patient treatments, with the domestic market serving as the primary sales channel. The company's focus on specialized medical devices for heart valve procedures, congenital heart conditions, and surgical repair applications drives its revenue streams. Beijing Balance Medical Technology's business model centers on developing and distributing high-precision medical devices tailored to specific surgical needs. The domestic Chinese healthcare system represents the main customer segment, with hospitals and clinics purchasing the company's products for use in cardiac surgeries, congenital heart defect corrections, and soft tissue repair operations. The company's product range directly supports medical procedures requiring biological heart valves, congenital heart disease interventions, and surgical tissue repair solutions. Beijing Balance Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beijing Balance Medical Technology Co stock

FCF Conversion Rate (FCF/EBITDA) of Beijing Balance Medical Technology Co is 31.82 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Beijing Balance Medical Technology Co changed from -18.47 % to 31.82 %, representing a -272.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Beijing Balance Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Beijing Balance Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Beijing Balance Medical Technology Co

All Key Metrics — Beijing Balance Medical Technology Co